This health tech company has made some significant changes in order to keep up with its growth. Photo via Getty Images

With a new CEO and chief operating officer aboard, Houston-based DataJoint is thinking small in order to go big.

Looking ahead to 2022, DataJoint aims to enable hundreds of smaller projects rather than a handful of mega-projects, CEO Dimitri Yatsenko says. DataJoint develops data management software that empowers collaboration in the neuroscience and artificial intelligence sectors.

"Our strategy is to take the lessons that we have learned over the past four years working with major projects with multi-institutional consortia," Yatsenko says, "and translate them into a platform that thousands of labs can use efficiently to accelerate their research and make it more open and rigorous."

Ahead of that shift, the startup has undergone some significant changes, including two moves in the C-suite.

Yatsenko became CEO in February after stints as vice president of R&D and as president. He co-founded the company as Vathes LLC in 2016. Yatsenko succeeded co-founder Edgar Walker, who had been CEO since May 2020 and was vice president of engineering before that.

In tandem with Yatsenko's ascent to CEO, the company brought aboard Jason Kirkpatrick as COO. Kirkpatrick previously was chief financial officer of Houston-based Darcy Partners, an energy industry advisory firm; chief operating officer and chief financial officer of Houston-based Solid Systems CAD Services (SSCS), an IT services company; and senior vice president of finance and general manager of operations at Houston-based SmartVault Corp., a cloud-based document management company.

"Most of our team are scientists and engineers. Recruiting an experienced business leader was a timely step for us, and Jason's vast leadership experience in the software industry and recurring revenue models added a new dimension to our team," Yatsenko says.

Other recent changes include:

  • Converting from an LLC structure to a C corporation structure to enable founders, employees, and future investors to be granted shares of the company's stock.
  • Shortening the business' name to DataJoint from DataJoint Neuro and recently launching its rebranded website.
  • Moving the company's office from the Texas Medical Center Innovation Institute (TMCx) to the Galleria area. The new space will make room for more employees. Yatsenko says the 12-employee startup plans to increase its headcount to 15 to 20 by the end of this year.

Over the past five years, the company's customer base has expanded to include neuroscience institutions such as Princeton University's Princeton Neuroscience Institute and Columbia University's Zuckerman Institute for Brain Science, as well as University College London and the Norwegian University of Science and Technology. DataJoint's growth has been fueled in large part by grants from the U.S. Defense Advanced Research Projects Agency (DARPA) and the Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative at the National Institutes of Health (NIH).

"The work we are tackling has our team truly excited about the future, particularly the capabilities being offered to the neuroscience community to understand how the brain forms perceptions and generates behavior," Yatsenko says.

A Houston-based software startup received a multimillion-dollar grant from the National Institutes of Health for its work within neurophysiology. Getty Images

Data science startup based in Houston focus on neuroscience software nabs $3.78M grant

brain game

Armed with a nearly $3.8 million federal grant, a Houston startup aims to boost neuroscience research around the world.

Vathes LLC, a developer of data management software that collaborates with neuroscience research labs in North America and Europe, recently received the $3.78 million grant from the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative at the National Institutes of Health (NIH). That initiative is part of the National Institute of Neurological Disorders and Stroke.

Vathes says the NIH funding will enable the startup to ramp up its DataJoint Pipelines for Neurophysiology project. The project aims to make open-source software for data science and engineering available to researchers who specialize in neurophysiology, a branch of neuroscience that looks at how the nervous system functions. The pipeline project holds the promise of benefiting research in areas like autism, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease).

The project's principal investigator is Dimitri Yatsenko, vice president of research and development at Vathes. Technologically speaking, neuroscientists are playing catch-up with their counterparts in fields like astrophysics, genomics, and bioinformatics, according to Yatsenko.

Neuroscience "is undergoing a fast transformation in terms of moving toward much more data-centric, data-intensive, computation-intensive, and collaborative projects," Yatsenko says. This means that neuroscientists are "now finding themselves having to quickly adapt to an environment," he adds, "where they have to share big data and computations with their collaborators in very dynamic settings and perform them in a very fluid way."

Yatsenko says the NIH-funded project will help smaller research groups tap into the technical expertise of larger research labs.

Vathes' DataJoint Neuro platform and services, which help create so-called DataJoint pipelines, enable neuroscientists to streamline, analyze, and visualize complex data. Among its customers are Princeton University's Neuroscience Institute and Columbia University's Zuckerman Institute. The federally funded project will empower smaller labs to capitalize on existing DataJoint pipelines as ready-to-go turnkey packages, Yatsenko says.

In essence, Vathes' technology acts as a translator. Big research labs collect data in databases that can vary by computer language and platform. Through the Vathes setup, that data can be incorporated by a lab of any size into algorithmic, machine learning, and artificial intelligence mechanisms, regardless of the computer language or platform.

Edgar Walker, CEO of Vathes, says this simplifies the construction and use of databases, giving scientists "more room to focus on the logic of their data pipeline rather than on the physical implementation of it."

Founded in 2016, Vathes is housed at the Texas Medical Center's Innovation Institute. It employs 10 people. The startup previously received a $100,000 grant from the U.S. Defense Advanced Research Projects Agency (DARPA).

Yatsenko says the project backed by the $3.78 million NIH grant will propel the startup's growth, as it "gives us a big window of opportunity" to provide tools and services that support the startup's open-source software.

"As the NIH and other funding agencies are shifting a lot of their focus to collaborative projects that are distributed among multiple institutions," Walker says, "we've established a reputation as the company that can facilitate such research, be efficient, and actually be cost-effective as well, and make the projects very smooth."

"We expect to continue to grow this business at the same exponential rate," he adds. "We'll keep our fingers crossed and see how things go."


CEO Edgar Walker (left) and Dimitri Yatsenko, vice president of research and development, lead Houston-based Vathes. Photos courtesy of Vathes

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”